MDR Antibodies

Santa Cruz Biotechnology features a diverse variety of MDR Antibodies targeting multidrug resistance proteins. MDR Antibodies are suitable for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Multidrug resistance proteins facilitate the transport of drugs and other substances across cellular membranes, significantly impacting the efficacy of chemotherapy and other therapeutic interventions. Understanding MDR protein function and regulation is essential for developing strategies to overcome drug resistance in cancer treatment. The study of multidrug resistance proteins continues to advance personalized medicine and improve patient outcomes. MDR protein research has revealed crucial insights into cellular defense mechanisms and therapeutic resistance patterns. Ongoing investigations of MDR proteins help identify novel therapeutic targets and potential drug resistance markers. Research utilizing Santa Cruz Biotechnology monoclonal antibodies contributes to advancing cancer treatment strategies and improving therapeutic outcomes worldwide.